ZGNX - ゾゲニクス （Zogenix Inc.）

Zogenix (NASDAQ: ZGNX ) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Zogenix missed estimated earnings by 11.36%, reporting an EPS of $-0.98 versus an … Full story available on Benzinga.com

Zogenix press release (ZGNX): Q4 GAAP EPS of -$0.98 misses by $0.10.Revenue of $26.6M (+212.9% Y/Y) beats by $0.2M.

EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021.

Zogenix Inc (ZGNX) shares closed today at 1.1% below its 52 week high of $26.57, giving the company a market cap of $1B. The stock is currently up 61.0% year-to-date, up 16.2% over the past 12 months, and up 171.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%. Trading Activity Trading volume this week was 74.2% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -793.4% The company's stock price performance over the past 12 months beats the peer average by -360.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

NEW YORK , Feb. 10, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 305 Broadway, 7 th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com SOC Telemed, Inc. (NASDAQ: TLMD ) Full story available on Benzinga.com

Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal.

Dealreporter flags Xenon Pharmaceuticals <> as a potential acquisition target following the agreement between Zogenix <> and UCB under which the Belgian drugmaker offered

A buyout deal is lighting a fire underneath the biotech''s shares today.

Zogenix ZGNX +68%. Vivos Therapeutics VVOS +33%. Cardiff Oncology CRDF -24%. Yumanity Therapeutics YMTX -17%.

Wall Street brokerages expect that Zogenix, Inc. (NASDAQ:ZGNX) will report $28.78 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Zogenixs earnings, with the highest sales estimate coming in at $39.00 million and the lowest estimate coming in at $25.00 million. Zogenix reported sales of $8.50 []

Zogenix, Inc. (NASDAQ:ZGNX) has been given an average recommendation of Buy by the eight ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year price []